FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.
Robert H. Jones(Velindre NHS Trust), John Chester(Velindre Cancer Centre), Paul M. Loadman(University of Bradford), Z. Boylan(Cancer Research UK), Syed A. Hussain(University Hospitals Plymouth NHS Trust), Pavlina Spiliopoulou(Beatson West of Scotland Cancer Centre), Kwame N. Atuah(AstraZeneca (United Kingdom)), Robert J. Jones(Beatson West of Scotland Cancer Centre), Tim Robinson(University of Bristol), Margaret A. Knowles(St James's University Hospital), Debbie Sherratt(University of Leeds), Dónal Landers(Clinical Research Institute), Sarah Brown(University of Leeds), Lyndall McLellan(Cancer Research UK), Simon J. Crabb(University of Southampton), Alison Birtle(University of Lancashire), David Alan Anthoney(St James's University Hospital), Chris Twelves(University of Leeds), Hazel Jones(Sarah Cannon), Louise Flanagan(University of Leeds)
Cited by 7
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k